Literature DB >> 27186311

Radiofrequency ablation for postsurgical thyroid removal of differentiated thyroid carcinoma.

Dong Xu1, Lipin Wang1, Bin Long2, Xuemei Ye2, Minghua Ge3, Kejing Wang3, Liang Guo3, Linfa Li2.   

Abstract

Differentiated thyroid carcinoma (DTC) is the most common endocrine malignancy. Surgical removal with radioactive iodine therapy is recommended for recurrent thyroid carcinoma, and the postsurgical thyroid removal is critical. This study evaluated the clinical values of radiofrequency ablation (RFA) in the postsurgical thyroid removal for DTC. 35 DTC patients who had been treated by subtotal thyroidectomy received RFA for postsurgical thyroid removal. Before and two weeks after RFA, the thyroid was examined by ultrasonography and (99m)TcO4 (-) thyroid imaging, and the serum levels of free triiodothyronine (FT3), free thyroxin (FT4), thyroid stimulating hormone (TSH) and thyroglobulin (Tg) were detected. The efficacy and complications of RFA were evaluated. Results showed that, the postsurgical thyroid removal by RFA was successfully performed in 35 patients, with no significant complication. After RFA, the average largest diameter and volume were significantly decreased in 35 patients (P > 0.05), and no obvious contrast media was observed in ablation area in the majority of patients. After RFA, the serum FT3, FT4 and Tg levels were markedly decreased (P < 0.05), and TSH level was significantly increased (P < 0.05). After RFA, radioiodine concentration in the ablation area was significantly reduced in the majority of patients. The reduction rate of thyroid update was 0.69±0.20%. DTC staging and interval between surgery and RFA had negative correlation (Pearson coefficient = -0.543; P = 0.001), with no obvious correlation among others influential factors. RFA is an effective and safe method for postsurgical thyroid removal of DTC.

Entities:  

Keywords:  Radiofrequency ablation; differentiated thyroid carcinoma; removal; ultrasonography

Year:  2016        PMID: 27186311      PMCID: PMC4859916     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  22 in total

1.  Complications encountered in the treatment of benign thyroid nodules with US-guided radiofrequency ablation: a multicenter study.

Authors:  Jung Hwan Baek; Jeong Hyun Lee; Jin Yong Sung; Jae-Ik Bae; Kyung Tae Kim; Jungsuk Sim; Seon Mi Baek; Young-sun Kim; Jung Hee Shin; Jeong Seon Park; Dong Wook Kim; Ji-hoon Kim; Eun-Kyung Kim; So Lyung Jung; Dong Gyu Na
Journal:  Radiology       Date:  2011-10-13       Impact factor: 11.105

2.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.

Authors:  David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

3.  Prospective randomized clinical trial to evaluate the optimal dose of 131 I for remnant ablation in patients with differentiated thyroid carcinoma.

Authors:  C Bal; A K Padhy; S Jana; G S Pant; A K Basu
Journal:  Cancer       Date:  1996-06-15       Impact factor: 6.860

4.  Comparison of 800 and 3700 MBq iodine-131 for the postoperative ablation of thyroid remnant in patients with low-risk differentiated thyroid cancer.

Authors:  Meltem Caglar; Fani M Bozkurt; Ceren Kapulu Akca; Sezen Elhan Vargol; Miyase Bayraktar; Omer Ugur; Ergun Karaağaoğlu
Journal:  Nucl Med Commun       Date:  2012-03       Impact factor: 1.690

5.  Optimal treatment strategy in patients with papillary thyroid cancer: a decision analysis.

Authors:  N F Esnaola; S B Cantor; S I Sherman; J E Lee; D B Evans
Journal:  Surgery       Date:  2001-12       Impact factor: 3.982

6.  Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer.

Authors:  Ujjal Mallick; Clive Harmer; Beng Yap; Jonathan Wadsley; Susan Clarke; Laura Moss; Alice Nicol; Penelope M Clark; Kate Farnell; Ralph McCready; James Smellie; Jayne A Franklyn; Rhys John; Christopher M Nutting; Kate Newbold; Catherine Lemon; Georgina Gerrard; Abdel Abdel-Hamid; John Hardman; Elena Macias; Tom Roques; Stephen Whitaker; Rengarajan Vijayan; Pablo Alvarez; Sandy Beare; Sharon Forsyth; Latha Kadalayil; Allan Hackshaw
Journal:  N Engl J Med       Date:  2012-05-03       Impact factor: 91.245

7.  Measurement of serum TSH and thyroid hormones in the management of treatment of thyroid carcinoma with radioiodine.

Authors:  C J Edmonds; S Hayes; J C Kermode; B D Thompson
Journal:  Br J Radiol       Date:  1977-11       Impact factor: 3.039

Review 8.  Radiofrequency ablation of benign thyroid nodules and recurrent thyroid cancers: consensus statement and recommendations.

Authors:  Dong Gyu Na; Jeong Hyun Lee; So Lyung Jung; Ji-Hoon Kim; Jin Yong Sung; Jung Hee Shin; Eun-Kyung Kim; Joon Hyung Lee; Dong Wook Kim; Jeong Seon Park; Kyu Sun Kim; Seon Mi Baek; Younghen Lee; Semin Chong; Jung Suk Sim; Jung Yin Huh; Jae-Ik Bae; Kyung Tae Kim; Song Yee Han; Min Young Bae; Yoon Suk Kim; Jung Hwan Baek
Journal:  Korean J Radiol       Date:  2012-03-07       Impact factor: 3.500

9.  Radiofrequency ablation to treat loco-regional recurrence of well-differentiated thyroid carcinoma.

Authors:  Sun Jin Lee; So Lyung Jung; Bum Soo Kim; Kook Jin Ahn; Hyun Seok Choi; Dong Jun Lim; Min Hee Kim; Ja Seong Bae; Min Sik Kim; Chan Kwon Jung; Se Min Chong
Journal:  Korean J Radiol       Date:  2014-11-07       Impact factor: 3.500

10.  Clinical experience with radioactive iodine in the treatment of childhood and adolescent Graves' disease.

Authors:  Adriano N Cury; Verônica T Meira; Osmar Monte; Marília Marone; Nilza M Scalissi; Cristiane Kochi; Luís E P Calliari; Carlos A Longui
Journal:  Endocr Connect       Date:  2012-12-05       Impact factor: 3.335

View more
  4 in total

1.  Radiofrequency ablation and thyroid nodules: updated systematic review.

Authors:  Haris Muhammad; Prasanna Santhanam; Jonathon O Russell
Journal:  Endocrine       Date:  2021-01-15       Impact factor: 3.633

2.  Diagnostic Value of Semiquantitative Analysis of 99mTechnetium-Methoxyisobutylisonitrile (99mTc-MIBI) Imaging in Predicting Early-Stage Cervical Lymph Node Metastasis of Thyroid Carcinoma.

Authors:  Xiao-Chun Zhu; Kai Zhou; Shi-Qing Xu; Yu-Bo Ma
Journal:  Med Sci Monit       Date:  2017-03-31

3.  Efficacy on radiofrequency ablation according to the types of benign thyroid nodules.

Authors:  Jianhua Li; Wenping Xue; Pengfei Xu; Zhen Deng; Caiwen Duan; Danhua Zhang; Shouhua Zheng; Kefei Cui; Xinguang Qiu
Journal:  Sci Rep       Date:  2021-11-15       Impact factor: 4.379

4.  HBME-1 expression in differentiated thyroid carcinoma and its correlation with the ultrasonic manifestation of thyroid.

Authors:  Jiwei Qiao; Chunyu Li; Yuying Zhang; Shuangyan Wang; Shan Gao
Journal:  Oncol Lett       Date:  2017-09-15       Impact factor: 2.967

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.